

Taste alteration in COVID-19: a rapid review with data synthesis reveals significant geographical differences

By

Nicola Cirillo

Melbourne Dental School, The University of Melbourne, 3053 Carlton, Victoria, Australia

***Address for Correspondence:**

Prof. Dr. Nicola Cirillo

Melbourne Dental School

The University of Melbourne

720 Swanston Street, Carlton

3053 Victoria, AUS

Tel/fax. +61 03 9341 1473

e-mail: nicola.cirillo@unimelb.edu.au

Abstract

To facilitate a timely understanding of the differences in the prevalence of gustatory disturbances (GD) in individuals infected with SARS-CoV-2, we undertook a rapid systematic review of articles published in the repository of the National Library of Medicine (MEDLINE/PubMed) and medRxiv from their inception until September 3, 2020. The minimum requirements for completing a restricted systematic review were met. Of the 431 articles retrieved, 61 eligible studies (28,374 confirmed COVID-19 cases) from 20 countries were included in the analysis. The results show strong significant differences in the overall reported prevalence of GD between East Asia [13%, 95% CI 0.14-26.06%], Middle East [38.83%, 95% CI 27.47-50.19%], Europe [57.18%, 95% CI 52.35-62.01%], and The Americas [66.78%, 95% CI 54.77-78.79%]. There were no trends showing differences of GD prevalence in the available literature between February and August, 2020. These data show that there is a distinct geographical distribution of GD in COVID-19 patients and this may explain the differences of diagnostic criteria for COVID-19 case definition.

Introduction

Early detection is key to reduce the spread of COVID-19 and is particularly challenging for asymptomatic or paucisymptomatic patients. Sudden loss of taste (ageusia), with or without loss of smell (anosmia) has been increasingly cited as independent symptoms or in association with the most common manifestations of the disease, such as fever, cough and fatigue (Guan et al., 2020). Unlike early studies (Lovato and de Filippis, 2020; O'Donovan et al., 2020), recent systematic reviews have shown that gustatory dysfunctions including ageusia, hypogeusia, and dysgeusia have a pooled prevalence of 81.6% of COVID-19 patients (Passarelli et al., 2020). Furthermore, loss of taste and smell have been reported to be distinguishing symptoms of COVID-19 with a high predictive value (Dawson et al., 2020). The European Centre for Disease Prevention and Control (ECDC) was one of the first public health bodies to include sudden onset of anosmia, ageusia or dysgeusia as chief clinical criteria to identify possible COVID-19 cases (ECDC, 2020). However, these symptoms have not been unanimously used for case identification and testing prioritization until August 2020. The Centers for Disease Control and Prevention (CDC) in the USA has updated COVID-19 case definition on 5 August to include new taste disorders as a chief clinical criterion for diagnosis (CDC, 2020). Soon afterwards (7 August), the World Health Organization (WHO) COVID-19 case definition was updated and included recent onset of ageusia, in the absence of any other identified cause, as suggestive of a probable COVID-19 case (WHO, 2020).

We hypothesized that differences in the criteria used for case identification of national or local public health bodies may reflect, at least in part, the changes of known prevalence rates of these symptoms over time and in a geographically specific manner. Because of the importance of the individuation of these trends in a timely fashion, we undertook a rapid systematic review with the

aim of gathering overall data on the prevalence of taste alterations worldwide and in four large geographical areas including East Asia, Middle East (including Turkey), Europe (including Britain), and the Americas.

Methods

Study design and literature search

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines and used a rapid review approach due to time constraints (Khangura et al., 2012). The minimum requirements for completing a restricted systematic review (Plüddemann et al., 2018) were met. Accordingly, the search was performed by one investigator (N.C.) and verification of random samples off full texts for the accuracy of title/abstract screening and data extraction was undertaken by the same reviewer. Key terms used for the search were (SARS-CoV-2 or COVID or COVID-19) AND (taste or ageusia or hypogeusia or dysgeusia or gustatory). The search was conducted in PubMed/MEDLINE as well as medRxiv using advanced search (title and abstract) tool.

Study selection and data extraction

The exclusion criteria were as follows: articles not in English, duplicate publications, irrelevant articles, studies where the infection status was not clearly confirmed, studies that did not evaluate gustatory outcomes individually, simple case reports, and review or systematic review articles. Studies using telephone surveys or Apps were only included where the respondents had a

confirmed COVID-19 diagnosis. For studies reporting on cases from two or more geographical areas (e.g. East Asia and Europe), data for subgroup analysis was extracted only when information from individual countries was available. Where end date of patient recruitment was not provided, date of article submission was used as a surrogate information. The primary outcome was to assess the prevalence of gustatory alterations (ageusia, hypogeusia, dysgeusia) in confirmed COVID-19 cases worldwide and in geographical areas, whereas the secondary outcome was to establish a spatiotemporal pattern of published cases. No constraints were placed on the size of the cohorts to ensure a comprehensive search and to identify the maximum number of potential articles.

Statistical analysis

Subgroup analyses were performed based on the country of origin of the studies by pooling the actual data reported in each individual study. Difference in prevalence and categories among subgroups was assessed with chi-square statistics and one-way ANOVA, as appropriate. Tukey's post-hoc test or Student's t test were used for comparison between group pairs. By making a further assumption that the dependent variable may not be normally distributed, the Kruskal-Wallis test was also used to compare overall differences in prevalence. Where appropriate, Pearson's coefficient was used to assess the correlation between time and prevalence. A level of $p < 0.05$ was chosen to determine statistical significance.

Results

Our search identified 431 studies and full text of 91 relevant articles meeting the inclusion criteria were assessed. Of these, 61 studies were included in the data synthesis (**Figure 1**). Studies were

from 20 different countries, and 5 derived from multi-national collaborations. Most cohorts were from Europe (n=40), followed by Middle East (n=8), North and South America (n=6 and n=2, respectively), East Asia (n=6) and Africa (n=1). Two articles (Lechien et al., 2020a; 2020b) pooled multinational data within Europe, whereas three studies (Chiesa-Estomba et al., 2020a; Menni et al., 2020; Qiu et al., 2020) included cases from two main geographical areas. Study populations and prevalence range are graphically depicted in **Figure 2**.

Worldwide, 14,486 out of 28,374 confirmed COVID-19 cases (51.05%) reported subjective and/or objective GD (**Table 1**). Strikingly, there were significant differences of prevalence between subgroups with either of the assumptions (ANOVA, $p < 0.000106$; Kruskal-Wallis, $p < 0.00071$). When comparing each geographical region, there were significant differences between all subgroups except Europe vs America (**Suppl Table 1**). Studies from East Asia reported the lowest prevalence of GD (13%, 95% CI 0.14-26.06%), followed by Middle East (38.83%, 95% CI 27.47-50.19%), Europe (57.18%, 95% CI 52.35-62.01%), and The Americas (66.78%, 95% CI 54.77-78.79). We could not find trends in differences in gross GD prevalence in COVID-19 patients over time, except in East Asia (**Supplementary Figure 1**).

Discussion

Awareness of the association between taste alterations and COVID-19 could be key for diagnosing the disease, particularly in dental and oral health settings (Cirillo, 2020). We followed a streamlined approach to synthesizing evidence, the rapid review, which is typically used for informing emergent decisions faced by decision makers in health care settings (Khangura et al.,

2012). The results of this rapid systematic review show that there are distinct geographical patterns of GD in patients with established SARS-CoV-2 infection.

The first systematic assessments of the evidence available up to March 2020 failed to identify associations between anosmia/ageusia and COVID-19 (Lovato and de Filippis, 2020; O'Donovan et al., 2020). For example, of the studies included in an early systematic review (with a total of 1556 patients), none reported about olfactory or gustative dysfunctions (Lovato and de Filippis, 2020). When looking specifically at the evidence for anosmia in COVID-19 up to 23 March, researchers found it to be “limited and inconclusive” (O'Donovan et al., 2020). The first study reporting a 5.1 and 5.6% prevalence of hyposmia and hypogeusia, respectively, was a pre-print (non-peer-reviewed) case series of a Chinese population (Mao et al., 2020). In sharp contrast, a most recent meta-analysis analyzing smell and taste alterations not only reported that almost half of COVID-19 patients had these symptoms but, also, that 15% of patients had olfactory and gustatory abnormalities as their initial symptoms (Chi et al., 2020).

Recent systematic reviews assessing chemosensory alterations in COVID-19 patients have been published (Abdullahi et al., 2020; Almqvist et al., 2020; Agyeman et al., 2020; von Bartheld et al., 2020; Borsetto et al., 2020; Carrillo-Larco et al., 2020; Chen et al., 2020; Chi et al., 2020; da Costa et al., 2020; Hoang et al., 2020; Passarelli et al., 2020; Printza et al., 2020; Romoli et al., 2020; Samaranayake et al., 2020; Struyf et al., 2020; Tong et al., 2020; Wang et al., 2020; Whittaker et al., 2020), however only one review was specifically focused on taste changes (Aziz et al., 2020). In their pooled analysis, Aziz et al. (2020) found that almost half of the patients (49.8%) with COVID-19 have altered taste sensation. In the reviews assessing chemosensory alterations, the range of olfactory and gustatory alterations, when reported individually, was 3.2-100% and 0-

92.6%, respectively. By and large, when the prevalence was pooled on the total number of cases examined, olfactory and gustatory alterations were found in approximately half of COVID-19 patients. Our data are in agreement with the existing literature on the worldwide incidence of GD: out of 28,374 confirmed COVID-19 cases, 14,486 (51.05%) reported GD. Overall, analysis of high-level evidence (Cirillo and Colella, unpublished) supports the inclusion of gustatory alterations as cardinal symptoms of COVID-19.

With regards to possible bias, it is to note that the majority of the studies are cross-sectional, retrospective observational studies, hence recollection bias may be present. Most studies are similar to those previously graded as “moderate risk of bias” (Tong et al., 2020). Importantly, the presence of taste alterations may not be reported in the presence of other severe symptoms, such as dyspnea, fever, and productive cough. This might explain the lack of association between GD and COVID-19 in the first studies published in February and March 2020 and the significant association with mild cases. For these reasons, the true prevalence of ageusia, hypogeusia and dysgeusia might be significantly higher than reported (Aziz et al., 2020).

Other potential weaknesses are that measures for assessing GD were not validated and that the definition of dysgeusia is not unanimously accepted. Furthermore, the awareness of the occurrence of taste alterations in COVID-19 cases may have determined and increase of self-reported GD over time (Menni et al., 2020), and/or this symptom may have been increasingly investigated by doctors when taking history of suspected cases. Although the latter remains a possibility, our data failed to show a trend of increased GD prevalence over time, except in East Asia. Unlike other studies (von Bartheld et al., 2020) our analysis focused on the geographical location of the studies rather than ethnicity. Although this approach may fail to individuate genetic/ethnic determinants of

infection, we believe that our methodology is better suited to study the clinical manifestations of the disease and to inform the decisions of public health surveillance bodies.

Most studies relied on the individuals reporting about their subjective (self-reported) impressions, whereas a small number of studies used structured (objective) tests to assess taste dysfunction, for example by using substances with the four basic tastes (sweet, sour, salty, bitter) sprayed on the tongue in a supra-threshold dose. When a comparison between subjective and structured (objective) gustatory function was made, no significant differences were found (Agyeman et al., 2020). Therefore, self-reported taste alterations can be considered a reliable parameter for investigating the prevalence of this condition in COVID-19 patients.

Conclusion

GD in COVID-19 show distinct geographical patterns. Given the potential usefulness of taste assessment in the diagnosis of mildly and paucisymptomatic patients, it is imperative to recognize ageusia/hypogeusia/dysgeusia as a potential clinical manifestation of COVID-19, particularly in Europe and America. Dentists may be the first healthcare providers to diagnose taste disturbances and are likely to play an important role in case identification and early diagnosis of COVID-19 cases in the near future.

Acknowledgements

N.C. would like to acknowledge the support of the Melbourne Dental School, The University of Melbourne.

References

- Abalo-Lojo JM, Pouso-Diz JM, Gonzalez F. Taste and Smell Dysfunction in COVID-19 Patients. *Ann Otol Rhinol Laryngol*. 2020; 129(10):1041-1042.
- Abdullahi A, Candan SA, Abba MA, et al. Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis. *Front Neurol*. 2020; 11:687. doi:10.3389/fneur.2020.00687
- Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. *Mayo Clin Proc*. 2020; 95:1621-1631.
- Al-Ani RM, Acharya D. Prevalence of Anosmia and Ageusia in Patients with COVID-19 at a Primary Health Center, Doha, Qatar. *Indian J Otolaryngol Head Neck Surg*. 2020 Aug 19:1-7. doi: 10.1007/s12070-020-02064-9.
- Almqvist J, Granberg T, Tzortzakakis A, et al. Neurological manifestations of coronavirus infections – a systematic review. *Ann Clin Transl Neurol* 2020; doi: 10.1002/acn3.51166.
- Altin F, Cingi C, Uzun T, Bal C. Olfactory and gustatory abnormalities in COVID-19 cases. *Eur Arch Otorhinolaryngol*. 2020 Jun 23:1-7. doi: 10.1007/s00405-020-06155-9.
- von Bartheld CS, Hagen MM, Butowt R. Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. *medRxiv*. 2020; doi:10.1101/2020.06.15.20132134
- Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study *Eur J Neurol*. 2020:10.1111/ene.14273. doi: 10.1111/ene.14273.
- Biadsee A, Biadsee A, Kassem F, Dagan O, Masarwa S, Ormianer Z. Olfactory and Oral Manifestations of COVID-19: Sex-Related Symptoms-A Potential Pathway to Early Diagnosis. *Otolaryngol Head Neck Surg*. 2020:194599820934380. doi: 10.1177/0194599820934380.
- Borsetto D, Hopkins C, Philips V, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. *Rhinology* 2020; doi: 10.4193/Rhin20.185.
- Brandao Neto D, Fornazieri MA, Dib C, et al. Chemosensory Dysfunction in COVID-19: Prevalences, Recovery Rates, and Clinical Associations on a Large Brazilian Sample. *Otolaryngol Head Neck Surg*. 2020 Sep 1:194599820954825. doi: 10.1177/0194599820954825.
- Çalica Utku A, Budak G, Karabay O, Güçlü E, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. *Scott Med J*. 2020;36933020949253. doi:10.1177/0036933020949253

Carignan A, Valiquette L, Grenier C, et al. Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case-control study. *CMAJ*. 2020; 192(26):E702-E707. doi: 10.1503/cmaj.200869.

Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A systematic review. *Wellcome Open Res*. 2020; 5:94. doi:10.12688/wellcomeopenres.15917.1

Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition, Approved August 5, 2020. <https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/>

Chary E, Carsuzaa F, Trijolet JP, et al. Prevalence and Recovery From Olfactory and Gustatory Dysfunctions in Covid-19 Infection: A Prospective Multicenter Study. *Am J Rhinol Allergy*. 2020; 34(5):686-693.

Chen X, Laurent S, Onur OA, et al. A systematic review of neurological symptoms and complications of COVID-19. *J Neurol*. 2020; 1-11. doi: 10.1007/s00415-020-10067-3.

Chi H, Chiu NC, Peng CC, et al. One-Seventh of Patients with COVID-19 Had Olfactory and Gustatory Abnormalities as Their Initial Symptoms: A Systematic Review and Meta-Analysis. *Life (Basel)*. 2020;10:E158. doi:10.3390/life10090158

Chiesa-Estomba CM, Lechien JR, Barillari MR, et al. Patterns of Gustatory Recovery in Patients Affected by the COVID-19 Outbreak. *Viol Sin*. 2020a; doi: 10.1007/s12250-020-00272-9.

Chiesa-Estomba CM, Lechien JR, Portillo-Mazal P, et al. Olfactory and gustatory dysfunctions in COVID-19. First reports of Latin-American ethnic patients. *Am J Otolaryngol*. 2020b; 41(5):102605. doi: 10.1016/j.amjoto.2020.102605. Epub 2020 Jun 6.

Cho RH, To ZW, Yeung ZW, et al. COVID-19 Viral Load in the Severity of and Recovery from Olfactory and Gustatory Dysfunction. *Laryngoscope*. 2020 Aug 13;10.1002/lary.29056. doi: 10.1002/lary.29056.

Cirillo N. COVID-19 outbreak: succinct advice for dentists and oral healthcare professionals. *Clin Oral Investig*. 2020; 24:2529-2535

da Costa KVT, Carnaúba ATL, Rocha KW, Andrade KCL, Ferreira SMS, Menezes PL. Olfactory and taste disorders in COVID-19: a systematic review. *Braz J Otorhinolaryngol*. 2020;S1808-8694(20)30066-5. doi:10.1016/j.bjorl.2020.05.008

Dawson P, Rabold EM, Laws RL, et al. Loss of Taste and Smell as Distinguishing Symptoms of COVID-19. *Clin Infect Dis*. 2020; doi:10.1093/cid/ciaa799

Dell'Era V, Farri F, Garzaro G, Gatto M, Aluffi Valletti P, Garzaro M. Smell and taste disorders during COVID-19 outbreak: Cross-sectional study on 355 patients. *Head Neck*. 2020; 42(7):1591-1596.

De Maria A, Varese P, Dentone C, Barisione E, Bassetti M. High prevalence of olfactory and taste disorder during SARS-CoV-2 infection in outpatients. *J Med Virol.* 2020 May 8;10.1002/jmv.25995. doi: 10.1002/jmv.25995.

European Centre for Disease Prevention and Control (ECDC). Case definition for coronavirus disease 2019 (COVID-19), as of 29 May 2020. <https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition>

Farah Yusuf Mohamud M, Garad Mohamed Y, Mohamed Ali A, Ali Adam B. Loss of Taste and Smell are Common Clinical Characteristics of Patients with COVID-19 in Somalia: A Retrospective Double Centre Study. *Infect Drug Resist.* 2020;13:2631-2635.

Faraji F, Prajapati DP, Boone CE, DeConde AS, Yan CH. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. *Int Forum Allergy Rhinol.* 2020;10(7):806-813.

Fistera D, Pabst D, Hartl A, et al., Separating the wheat from the chaff-COVID-19 in a German emergency department: a case-control study. *Int J Emerg Med.* 2020 Aug 20;13(1):44. doi: 10.1186/s12245-020-00302-z.

Gelardi M, Trecca E, Cassano M, Ciprandi G. Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report. *Acta Biomed.* 2020; 91(2):230-231

Giacomelli A, Pezzati L, Conti F, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. *Clin Infect Dis.* 2020; 71(15):889-890.

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; 382:1708-1720.

Hintschich CA, Wenzel JJ, Hummel T, et al. Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients. *Int Forum Allergy Rhinol.* 2020 Jul 1:10.1002/alr.22655. doi: 10.1002/alr.22655.

Hoang MP, Kanjanaumporn J, Aeumjaturapat S, Chusakul S, Seresirikachorn K, Snidvongs K. Olfactory and gustatory dysfunctions in COVID-19 patients: A systematic review and meta-analysis. *Asian Pac J Allergy Immunol* 2020; doi:10.12932/AP-210520-0853

Izquierdo-Dominguez A, Rojas-Lechuga MJ, Chiesa-Estomba C, et al. Smell and taste dysfunctions in COVID-19 are associated with younger age in ambulatory settings - a multicenter cross-sectional study. *J Investig Allergol Clin Immunol.* 2020 Jun 17:0. doi: 10.18176/jiaci.0595.

Kempker RR, Kempker JA, Peters M, et al. Loss of Smell and Taste Among Healthcare Personnel Screened for Coronavirus 2019. *Clin Infect Dis.* 2020 Jun 28:ciaa877. doi: 10.1093/cid/ciaa877.

Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries: the evolution of a rapid review approach. *Syst Rev.* 2012;1:10. Published 2012 Feb 10. doi:10.1186/2046-4053-1-10

Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect.* 2020; 26(7):948.e1-948.e3. doi: 10.1016/j.cmi.2020.04.040. Epub 2020 May 1.

Klopfenstein T, Zahra H, Kadiane-Oussou NJ, et al. New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France. *Int J Infect Dis.* 2020 Aug 6:S1201-9712(20)30637-8. doi: 10.1016/j.ijid.2020.08.012.

Lapostolle F, Schneider E, Vianu I, et al. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. *Intern Emerg Med.* 2020;15(5):813-817.

Lechien JR, Chiesa-Estomba CM, De Siaty DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol.* 2020a;277(8):2251-2261

Lechien JR, Chiesa-Estomba CM, Hans S, et al. Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19. *Ann Intern Med.* 2020b; doi: 10.7326/M20-2428.

Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med.* 2020c; 288(3):335-344

Lee DJ, Lockwood J, Das P, Wang R, Grinspun E, Lee JM. Self-reported anosmia and dysgeusia as key symptoms of coronavirus disease 2019. *CJEM.* 2020; doi: 10.1017/cem.2020.420.

Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. *J Korean Med Sci.* 2020; 35:e174. doi: 10.3346/jkms.2020.35.e174. Lovato A, de Filippis C. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. *Ear Nose Throat J* 2020; *in press* doi:10.1177/0145561320920762

Levinson R, Elbaz M, Ben-Ami R, et al. Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection. *Infect Dis (Lond).* 2020;52(8):600-602.

Liang Y, Xu J, Chu M, et al. Neurosensory dysfunction: A diagnostic marker of early COVID-19. *Int J Infect Dis.* 2020; 98:347-352.

Liguori C, Pierantozzi M, Spanetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun.* 2020; 88:11-16. doi: 10.1016/j.bbi.2020.05.037.

Luers JC, Rokohl AC, Loreck N, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19). *Clin Infect Dis.* 2020:ciaa525. doi: 10.1093/cid/ciaa525.

Magnavita N, Tripepi G, Di Prinzio RR. Symptoms in Health Care Workers during the COVID-19 Epidemic. A Cross-Sectional Survey. *Int J Environ Res Public Health.* 2020;17(14):5218. doi: 10.3390/ijerph17145218.

Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.* 2020; 77(6):1-9. doi: 10.1001/jamaneurol.2020.1127.

Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. *medRxiv* 2020.02.22.20026500; doi: <https://doi.org/10.1101/2020.02.22.20026500>

Martin-Sanz E, Riestra J, Yebra L, et al. Prospective study in 355 patients with suspected COVID-19 infection. Value of cough, subjective hyposmia, and hypogeusia. *Laryngoscope.* 2020 Jul 20:10.1002/lary.28999. doi: 10.1002/lary.28999.

Meini S, Suardi LR, Busoni M, Roberts AT, Fortini A. Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life. *Eur Arch Otorhinolaryngol.* 2020; doi: 10.1007/s00405-020-06102-8.

Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med.* 2020; 26(7):1037-1040.

Mercante G, Ferreli F, De Virgilio A, et al. Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019. *JAMA Otolaryngol Head Neck Surg.* 2020; 146(8):1-6. doi: 10.1001/jamaoto.2020.1155.

O'Donovan J, Tanveer S, Jones N, et al. Sniffing out the evidence for olfactory symptoms as a clinical feature of COVID-19: A systematic scoping review. *Centre for Evidence-Based Medicine* 2020 <https://www.cebm.net/wp-content/uploads/2020/03/Rapid-Review-Anosmia-COVID19.pdf>

Paderno A, Schreiber A, Grammatica A, et al. Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts. *Int Forum Allergy Rhinol.* 2020; 10(8):955-962. doi: 10.1002/alr.22610.

Passarelli PC, Lopez MA, Mastandrea Bonaviri GN, Garcia-Godoy F, D'Addona A. Taste and smell as chemosensory dysfunctions in COVID-19 infection. *Am J Dent.* 2020;33(3):135-137.

Patel A, Charani E, Ariyanayagam D, et al. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. *Clin Microbiol Infect.* 2020; 26(9):1236-41.

Petrocelli M, Ruggiero F, Baietti AM, et al. Remote psychophysical evaluation of olfactory and gustatory functions in early-stage coronavirus disease 2019 patients: the Bologna experience of 300 cases. *J Laryngol Otol.* 2020; 134(7):571-576.

Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline. *J Neurol Sci.* 2020; 415:116969. doi: 10.1016/j.jns.2020.116969.

Plüddemann A, Aronson JK, Onakpoya I, Heneghan C, Mahtani KR. Redefining rapid reviews: a flexible framework for restricted systematic reviews. *BMJ Evid Based Med.* 2018;23(6):201-203. doi:10.1136/bmjebm-2018-110990

Poncet-Megemont L, Paris P, Tronchere A, et al. High Prevalence of Headaches During Covid-19 Infection: A Retrospective Cohort Study. *Headache*. 2020 Aug 5:10.1111/head.13923. doi: 10.1111/head.13923.

Printza A, Constantinidis J. The role of self-reported smell and taste disorders in suspected COVID-19. *Eur Arch Otorhinolaryngol*. 2020;277(9):2625-2630.

Qiu C, Cui C, Hautefort C, et al. Olfactory and Gustatory Dysfunction as an Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study. *Otolaryngol Head Neck Surg*. 2020:194599820934376. doi: 10.1177/0194599820934376.

Rojas-Lechuga MJ, Izquierdo-Dominguez A, Chiesa-Estomba C, et al. Chemosensory dysfunction in COVID-19 out-patients. *Eur Arch Otorhinolaryngol*. 2020 Aug 25:1-8. doi: 10.1007/s00405-020-06266-3.

Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. *Neurology*. 2020; 95(8):e1060-e1070. doi:10.1212/WNL.0000000000009937.

Romoli M, Jelcic I, Bernard-Valnet R, et al. A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details. *Eur J Neurol*. 2020; doi:10.1111/ene.14382

Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. *Am J Otolaryngol*. 2020;41(6):102622. doi: 10.1016/j.amjoto.2020.102622.

Salepci E, Turk B, Ozcan SN, et al. Symptomatology of COVID-19 from the otorhinolaryngology perspective: a survey of 223 SARS-CoV-2 RNA-positive patients. *Eur Arch Otorhinolaryngol*. 2020; doi: 10.1007/s00405-020-06284-1.

Samaranayake LP, Fakhruddin KS, Panduwawala C. Sudden onset, acute loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic review. *Acta Odontol Scand*. 2020; 78:467-473.

Sayin İ, Yaşar KK, Yazici ZM. Taste and Smell Impairment in COVID-19: An AAO-HNS Anosmia Reporting Tool-Based Comparative Study. *Otolaryngol Head Neck Surg*. 2020;163(3):473-479.

Sierpiński R, Pinkas J, Jankowski M, et al. Sex differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders in 1942 nonhospitalized patients with coronavirus disease 2019 (COVID-19). *Pol Arch Intern Med*. 2020;130(6):501-505.

Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database Syst Rev*. 2020;7(7):CD013665. doi: 10.1002/14651858.CD013665

Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck Surg.* 2020;163(1):3-11.

Tudrej B, Sebo P, Lourdaux J, et al. Self-Reported Loss of Smell and Taste in SARS-CoV-2 Patients: Primary Care Data to Guide Future Early Detection Strategies. *J Gen Intern Med.* 2020; 35(8):2502-2504. doi: 10.1007/s11606-020-05933-9.

Vacchiano V, Riguzzi P, Volpi L, et al. Early neurological manifestations of hospitalized COVID-19 patients. *Neurol Sci.* 2020;41(8):2029-2031.

Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. *Head Neck.* 2020a; 42(6):1252-1258.

Vaira LA, Hopkins C, Petrocelli M, et al. Do olfactory and gustatory psychophysical scores have prognostic value in COVID-19 patients? A prospective study of 106 patients. *J Otolaryngol Head Neck Surg.* 2020b; 49(1):56. doi: 10.1186/s40463-020-00449-y.

Vaira LA, Hopkins C, Petrocelli M, et al. Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study. *J Laryngol Otol.* 2020c; doi: 10.1017/S0022215120001826.

Vaira LA, Hopkins C, Salzano G, et al. Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study. *Head Neck.* 2020d;42(7):1560-1569.

Villarreal IM, Morato M, Martinez-RuizCoello M, et al. Olfactory and taste disorders in healthcare workers with COVID-19 infection. *Eur Arch Otorhinolaryngol.* 2020 Jul 28:1-5. doi: 10.1007/s00405-020-06237-8.

Wang L, Shen Y, Li M, et al. Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. *J Neurol.* 2020;1-13. doi:10.1007/s00415-020-09974-2

Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. *Acta Neurol Scand.* 2020;142(1):14-22.

World Health Organization. WHO COVID-19 Case definition, published 7 August 2020 https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2020.1

Zayet S, Kadiane-Oussou NJ, Lepiller Q, et al. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. *Microbes Infect.* 2020a; S1286-4579(20)30094-0. doi: 10.1016/j.micinf.2020.05.016.

Zayet S, Klopfenstein T, Mercier J, et al. Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients. *Infection.* 2020b; doi: 10.1007/s15010-020-01442-3.

Tables and Figures

Table 1. Studies included for the evaluation of gustatory dysfunction (GD).

Reference	GD	COVID+	Prevalence	Area
Romero-Sanchez et al, 2020	52	841	6.2%	Spain
Paderno et al., 2020	320	508	63%	Italy
Zayet et al., 2020b	62	95	65%	France
Vaira et al., 2020a	39	72	54.2%	Italy
Lapostolle et al., 2020	757	1487	50.9%	France
Martin-Sanz et al., 2020	114	215	53%	Spain
Lechien et al., 2020c	770	1420	54.2%	Europe (multiple sites)
Villarreal et al., 2020	161	230	70%	Spain
Petrocelli et al., 2020	184	300	61.3%	Italy
Qiu C et al., 2020	50, 20	116, 39	45.16%	France, Germany (and China)
Abalo-Lojo et al., 2020	74	131	56.5%	Spain
Zayet et al., 2020a	34	70	48.6%	France
Tudrej et al., 2020	92	198	46.5%	France
Poncet-Megemont et al., 2020	81	139	58.3%	France
Patel et al., 2020	89	141	63.1%	UK
Chary et al., 2020	64	115	55.65%	France
Sierpinski et al., 2020	923	1942	47.5%	Poland
Izquierdo-Dominguez et al., 2020	442	846	52.2%	Spain
Rojas-Lechuga et al., 2020	128	197	65%	Spain
Giacomelli et al., 2020	17	59	28.8%	Italy
Menni et al., 2020	4178	6452	64.76%	UK (and USA)
Vaira et al., 2020b	76	106	71.7%	Italy
Mercante et al., 2020	113	204	55.4%	Italy
Lechien et al., 2020b	1136	2013	56%	Europe (multiple sites)
Klopfenstein et al., 2020	34	70	48%	France
Liguori et al., 2020	48	103	46.6%	Italy
Luers et al., 2020	50	72	69.4%	Germany
Dell'Era et al., 2020	232	355	65.4%	Italy
Magnavita et al., 2020	31	82	37.8%	Italy
Meini et al., 2020	69	100	69%	Italy
Lechien et al., 2020a	342	385	88.8%	Belgium
Beltrán-Corbellini et al, 2020	28	79	35.44%	Spain
Vaira et al., 2020d	234	340	67.8%	Italy
Gelardi et al., 2020	52	72	72.2%	Italy
Vacchiano et al., 2020	66	108	61%	Italy
De Maria et al., 2020	48	95	50.5%	Italy

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Fistera et al., 2020	6	43	14%	Germany
Vaira et al., 2020c	91	138	65.9%	Italy
Hintschich et al., 2020	18	41	44%	Germany
Chiesa-Estomba et al., 2020a	718	1043	68.8%	Europe (multiple sites)
	12,043	21,062	57.18%	TOTAL EUROPE
Yan et al., 2020	42	59	71%	USA
Menni et al., 2020	490	726	67.49%	USA (and UK)
Carignan et al., 2020	85	134	63.4%	Canada
Pinna et al., 2020	10	50	10%	USA
Chiesa-Estomba et al., 2020	333	542	61.4%	South America (Multiple sites)
Lee et al., 2020	32	56	57.1%	Canada
Kempker et al., 2020	27	51	52.9%	USA
Brandao Neto et al., 2020	499	655	76.2%	Brazil
	1518	2273	66.78%	TOTAL AMERICA
Sayin et al., 2020	46	64	71.9%	Turkey
Biadsee et al., 2020	67	128	52%	Israel
Altin et al., 2020	22	81	27.2%	Turkey
Salepci et al., 2020	77	223	34.5%	Turkey
Al-Ani and Acharya, 2020	28	141	19.86%	Qatar
Sakalli et al., 2020	81	172	47.1%	Turkey
Levinson et al., 2020	14	42	33.3%	Israel
Çalica Utku et al., 2020	51	143	35.7%	Turkey
	386	994	38.83%	TOTAL MIDDLE EAST
Lee et al., 2020	353	3191	11%	Korea
Mao et al., 2020	12	214	5.6%	China
Kim et al., 2020	58	172	33.7%	Korea
Qiu et al., 2020	30	239	12.55%	China (and France, Germany)
Cho et al., 2020	36	83	43.4%	Hong Kong
Liang et al., 2020	33	86	38.4%	China
	522	3985	13.1%	TOTAL EAST ASIA
Farah YMM et al., 2020	17	60	28.3%	Somalia
	14,486	28,374	50.05%	WORLD

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart of study selection process.






Figure 2. Worldwide prevalence of gustatory disorders (GD) in COVID-19 positive cases. Circle size is proportional to study population.



Supplementary Material

Supplementary Figure 1. Reported prevalence (%) of GD in COVID-19 patients from February to August, 2020. End date of recruitment or date of submission was used to identify a temporal category.



Supplementary Table 1. *p* value of student's t test comparing subgroups

	East Asia	Middle East	Europe	America
East Asia		0.047	0.002	0.001
Middle East	0.047		0.02	0.023
Europe	0.002	0.02		0.29
America	0.001	0.023	0.29	